Folate deficiency anemia

Article written and reviewed by Dr Luca Moretti

Folate deficiency anemia, also known as megaloblastic anemia due to folic acid deficiency, is a hematologic condition characterized by insufficient availability of folates, essential cofactors in nucleic acid and amino acid metabolism. This type of anemia is characterized by increased red blood cell size (macrocytes), a hematologic and bone marrow picture marked by megaloblastosis and morphologic abnormalities of hematopoietic cells, together with systemic manifestations predominantly involving the hematopoietic system and gastrointestinal tract. Unlike vitamin B12 deficiency, folate deficiency does not typically cause subacute combined degeneration; rare neurologic manifestations have also been described in isolated deficiency.

Folate deficiency may result from several mechanisms, including reduced dietary intake, increased requirements, intestinal malabsorption or drug interference. At-risk situations include malnutrition, pregnancy, chronic hemolysis, intestinal disease and prolonged use of certain drugs. Clinically, the disorder develops insidiously, often with initially subtle symptoms that, without treatment, progress to macrocytic anemia, pancytopenia and general asthenic symptoms.

Diagnosis is based on integration of clinical data, specific laboratory tests and assessment of predisposing factors, whereas treatment is based on prompt correction of the deficiency and identification of the underlying cause, allowing rapid remission of the hematologic picture and prevention of hematologic and obstetric complications, especially in vulnerable individuals.

Etiology and risk factors

Folate deficiency may result from numerous factors related to the complexity of the metabolism of these water-soluble vitamins and the central role folates play in cellular biosynthetic processes. Folates are obtained from the diet through green leafy vegetables, legumes, fruit, liver and whole grains; however, they are particularly sensitive to heat and light and may be rapidly degraded during cooking or food storage.

Causes of folate deficiency include:

• Reduced dietary intake: the most common cause worldwide, due to diets low in fresh vegetables, alcoholism, malnutrition, restrictive diets, socioeconomic disadvantage or poor dietary habits. Infants exclusively breastfed by folate-deficient mothers may also develop deficiency.
• Increased requirements: folate requirements rise markedly during pregnancy, breastfeeding, rapid growth (childhood, adolescence), chronic hemolytic anemia, rapidly proliferating neoplasms, chronic inflammatory diseases and dialysis.
• Intestinal malabsorption: diseases impairing absorption in the proximal small intestine, the primary site of folate absorption, such as celiac disease, Crohn disease, tropical sprue, intestinal resections, malabsorption syndromes and some chronic infections.
• Drug interference: drugs that inhibit folate metabolism or absorption (methotrexate, trimethoprim, anticonvulsants such as phenytoin, barbiturates, sulfasalazine, some antineoplastic and antituberculosis drugs) may cause deficiency even when dietary intake is adequate.
• Other rare causes: genetic abnormalities affecting folate transport, reduction or polyglutamation, chronic liver failure and excessive renal folate loss (nephrotic syndrome, chronic dialysis).

The main risk factors for folate deficiency anemia include:

• Chronic alcoholism (reduced intake, intestinal malabsorption, increased hepatic folate metabolism).
• Pregnancy and breastfeeding, periods of rapid growth and conditions of increased metabolic demand.
• Chronic gastrointestinal diseases (celiac disease, Crohn disease, tropical sprue, intestinal resections).
• Prolonged use of folate-antagonist drugs (methotrexate, phenytoin, barbiturates, trimethoprim, sulfonamides).
• Diet low in fresh vegetables and fruit or chronic malnutrition.
• Chronic hemolysis (hereditary or acquired hemolytic anemias, sickle cell disease, spherocytosis, thalassemia major).
• Chronic liver or kidney failure.

These factors increase individual vulnerability and the likelihood of developing deficiency, particularly when they coexist or persist for long periods.

Epidemiologically, folate deficiency is more frequent in populations with limited access to a varied diet, unsupplemented pregnant women, people with chronic diseases and patients treated with folate-antagonist drugs. Unlike vitamin B12, body folate stores are more limited (1-3 months), so deficiency may develop relatively quickly when intake or absorption is inadequate.

Pathogenesis and pathophysiology

The pathophysiology of folate deficiency anemia is based on disruption of key processes in nucleotide metabolism and nucleic acid synthesis, with profound consequences especially in tissues with rapid cellular turnover such as bone marrow. Folates are essential cofactors in one-carbon transfer reactions required for synthesis of thymidine, purines and numerous amino acids, as well as DNA methylation and epigenetic regulation.

• Dietary intake: folates are obtained mainly from fresh green leafy vegetables, legumes, citrus fruits, liver and grains. Dietary deficiency may result from diets poor in fresh foods, prolonged cooking, malnutrition or conditions that reduce overall caloric intake.
• Intestinal absorption: most dietary folates are present as polyglutamates, which are hydrolyzed in the proximal small intestine to monoglutamates before absorption. Diseases damaging jejunal mucosa, such as celiac disease or Crohn disease, intestinal resections and chronic infections reduce absorptive capacity, causing rapid depletion of body stores.
• Transport and metabolism: after absorption, folates are transported to the liver and tissues in reduced forms, mainly as tetrahydrofolate (THF) and its derivatives, which act as one-carbon unit donors in nucleic acid synthesis. Drug interference (antifolates such as methotrexate, anticonvulsants) and genetic abnormalities may reduce the activity of enzymes involved in folate conversion and utilization.
• Increased requirements or losses: conditions accelerating cellular turnover, such as pregnancy, growth, hemolytic anemia or proliferative diseases, increase folate requirements beyond the compensatory capacity of body stores. Renal or dialytic losses may promote deficiency in predisposed individuals.

At the cellular level, the main role of folates concerns synthesis of thymidine monophosphate (dTMP) from deoxyuridine monophosphate (dUMP), a reaction catalyzed by thymidylate synthase and essential for DNA production. Without adequate folate availability, dTMP synthesis is impaired, causing defective DNA synthesis and blockade of cell division, particularly evident in bone marrow erythroid precursors. These cells, unable to complete DNA replication correctly, undergo cytoplasmic maturation without corresponding nuclear maturation, producing megaloblasts, large cells with an immature nucleus and mature cytoplasm.

The resulting picture is one of ineffective erythropoiesis, with increased intramedullary apoptosis of hematopoietic precursors, reduced production of mature erythrocytes, development of macrocytic anemia and often pancytopenia because the granulocytic and megakaryocytic lineages are also involved. The peripheral smear shows oval macrocytes, anisopoikilocytosis, hypersegmented granulocytes and platelets that are enlarged but reduced in number.

Unlike vitamin B12 deficiency, folate deficiency does not typically cause subacute combined degeneration of the spinal cord. Rare neuropathy, myelopathy and neuropsychiatric manifestations have nevertheless been described in isolated folate deficiency. Hyperhomocysteinemia may accompany the deficiency and is observationally associated with vascular risk, but does not by itself establish causality.

During pregnancy, folate deficiency is particularly important because of the risk of neural tube defects (spina bifida, anencephaly) in the fetus, reflecting the essential role of folates in cell division and early embryonic development. Supplementation is therefore recommended for all women of childbearing potential and during pregnancy.

Overall, the pathophysiology of folate deficiency anemia reflects the close dependence of DNA synthesis and cell division on folate availability: deficiency initiates a cascade of events resulting in anemia, cytopenias and, in vulnerable patients, major obstetric complications; associated hyperhomocysteinemia does not establish a direct causal thrombotic risk.

Clinical manifestations

The clinical picture of folate deficiency anemia develops insidiously and is often asymptomatic in the early stages, with progressive worsening of symptoms in prolonged or severe forms. Hematologic manifestations represent the main component of the clinical presentation. Patients typically report asthenia, easy fatigability, exertional dyspnea and compensatory tachycardia. Macrocytic megaloblastic anemia develops slowly and is relatively well tolerated, but advanced cases may present with skin and mucosal pallor, palpitations, headache, tinnitus, and may worsen angina or heart failure in already frail patients. Blood smear examination shows oval macrocytes, marked anisopoikilocytosis and hypersegmented granulocytes; prolonged deficiency may cause pancytopenia, neutropenia and thrombocytopenia with risk of recurrent infections and bleeding. Reticulocytopenia is common and reflects ineffective erythroid production, while mild jaundice may result from increased catabolism of erythroid precursors.

Unlike vitamin B12 deficiency, neurologic manifestations are rare and do not show the typical pattern of subacute combined degeneration. Peripheral neuropathy, myelopathy and neuropsychiatric disturbances have nevertheless been described in isolated folate deficiency. Hyperhomocysteinemia may accompany the deficiency and is observationally associated with vascular risk but does not establish a specific causal relationship.

Gastrointestinal manifestations are often subtle and include atrophic glossitis, with a smooth, red and painful tongue, sometimes associated with angular cheilitis, stomatitis, altered taste and oral burning. Anorexia, weight loss, nausea, dyspeptic symptoms, intermittent diarrhea or constipation may occur, especially in patients with malabsorption disorders.

Systemic manifestations include asthenia, apathy, weight loss and reduced general performance. Hyperhomocysteinemia may be present and is observationally associated with vascular risk, without evidence of specific causality from folate deficiency.

A specific concern is pregnancy and childhood: maternal folate deficiency, even when subclinical, is associated with a significantly increased risk of neural tube defects (spina bifida, anencephaly) and other congenital malformations in the fetus, as well as obstetric complications such as intrauterine growth restriction and preterm birth. In children, especially with malnutrition or multiple deficiencies, impaired linear and weight growth, lethargy and poor appetite may occur; psychomotor delay is not a specific isolated manifestation of folate deficiency.

Diagnosis and investigations

Diagnosis of folate deficiency anemia is based on careful correlation of history, clinical data and laboratory findings, with the aim of identifying the deficiency and distinguishing it from other causes of megaloblastic anemia, particularly vitamin B12 deficiency. Suspicion arises in patients with known risk factors, symptoms of progressive anemia and compatible findings on complete blood count.

The complete blood count is the first investigation and typically shows macrocytic anemia (often with MCV >100 fL), but macrocytosis may be absent or masked, for example by concomitant iron deficiency. Reduced hemoglobin of variable severity may be observed, while leukopenia and thrombocytopenia are less constant findings and occur mainly in more advanced or prolonged disease, reflecting global impairment of bone marrow hematopoiesis.

Examination of the peripheral blood smear typically shows oval macrocytes and hypersegmented granulocytes, findings highly suggestive of megaloblastic anemia, while abnormalities such as anisopoikilocytosis and enlarged but reduced platelets are frequent but nonspecific. In chronic disease, a mild increase in indirect bilirubin and LDH may be present, indirect signs of ineffective erythropoiesis and intramedullary precursor lysis.

Serum folate measurement is the first-line biochemical test; interpretation depends on the analytic method and laboratory. Red-cell folate is not routinely required and may be reserved for selected cases. When laboratory findings are inconclusive, plasma homocysteine may be useful: hyperhomocysteinemia is common in both folate and vitamin B12 deficiency, but methylmalonic acid remains normal in folate deficiency, distinguishing it from cobalamin deficiency, in which it is increased.

Concomitant vitamin B12 deficiency must always be excluded by measuring serum cobalamin, because isolated folate administration in vitamin B12 deficiency may mask the anemia without preventing neurologic complications.

A detailed history should investigate dietary habits, chronic gastrointestinal diseases (such as celiac disease, Crohn disease, sprue, intestinal resections), prolonged use of folate-antagonist drugs and conditions of increased requirement (pregnancy, chronic hemolysis, neoplasms), in order to guide investigation of the underlying cause and establish targeted treatment.

Only in atypical cases or megaloblastic anemia without a clear diagnosis is bone marrow examination performed; it shows erythroid hyperplasia and megaloblasts with asynchronous nuclear-cytoplasmic maturation, findings that are suggestive but not specific for folate deficiency.

In children or cases with suspected congenital abnormalities of folate metabolism, specialist genetic and metabolic investigations may be indicated.

In summary, diagnosis requires correlation of a compatible hematologic picture, which may be macrocytic but may also be masked by concomitant deficiencies, reduced folate levels and assessment of possible predisposing factors or associated conditions, with particular attention to concomitant or overlapping nutritional deficiencies.

Treatment and prognosis

Treatment of folate deficiency anemia is based on prompt correction of the deficiency, elimination of the underlying cause and prevention of complications, with particular attention to vulnerable groups such as pregnant women, children and patients with chronic comorbidities. Treatment is generally simple and highly effective when started early.

Folic acid administration is the cornerstone of treatment: oral folic acid is generally given at a dose of 5 mg daily for approximately four months, with different doses or durations in selected conditions, until hematologic parameters normalize. In severe malabsorption or when oral administration is not possible, parenteral administration may be considered, although it is rarely necessary. In patients with deficiency secondary to chronic hemolysis, pregnancy or other conditions of increased requirements, therapy may be prolonged or continued as prophylactic supplementation.

Before treatment begins, concomitant vitamin B12 deficiency must always be excluded, because folate administration in cobalamin deficiency may correct the hematologic abnormalities and mask B12 deficiency while neurologic injury continues to progress.

Correction of the deficiency generally produces a rapid clinical and laboratory response: within a few days, a reticulocyte response occurs, followed by gradual normalization of hemoglobin, MCV and other hematologic parameters. Complete remission typically occurs within 4-8 weeks. Systemic symptoms progressively improve, while obstetric complications require specific surveillance in patients at risk.

Prevention of recurrence is based on nutritional education, supplementation in at-risk populations and management of predisposing factors. Regular folic acid supplementation is recommended in women of childbearing potential and during pregnancy to reduce the risk of congenital fetal defects and obstetric complications. Long-term treatment may be necessary in patients with chronic malabsorption, intestinal disease or treatment with folate-antagonist drugs.

The prognosis of folate deficiency anemia is generally favorable when deficiency is recognized and corrected early. Hematologic abnormalities are completely reversible, whereas the risk of permanent complications mainly concerns unsupplemented pregnancies and forms associated with inadequately treated chronic conditions. Periodic clinical and laboratory monitoring is essential in people at risk of recurrence.

Complications

The complications of folate deficiency anemia occur mainly when deficiency persists or is not recognized promptly. The principal consequences concern worsening hematopoietic function and effects on fetal development during pregnancy.

Hematologic complications include progression to severe pancytopenia, with marked anemia, neutropenia and thrombocytopenia that expose patients to recurrent infections, bleeding and, in frail individuals, heart failure or worsening of pre-existing disease. Chronic deficiency may cause major deterioration in quality of life and general condition.

Persistent hyperhomocysteinemia is observationally associated with vascular risk but does not establish a direct causal role of folate deficiency in thrombosis, stroke or myocardial infarction.

During pregnancy, the most feared complication is neural tube defects (spina bifida, anencephaly) and other congenital malformations; associations are also described with intrauterine growth restriction, miscarriage, preterm birth and neonatal mortality. The risk of neural tube defects is reduced by periconceptional folic acid supplementation started before conception and continued in early pregnancy; the other outcomes are not all completely preventable by folate supplementation alone.

Chronic persistence of the condition may lead to progressive asthenia, malnutrition, loss of autonomy and worsening of all chronic comorbidities, especially in older adults or people with concomitant diseases.

Prompt identification and correction of folate deficiency is therefore crucial for resolving the hematologic abnormalities, correcting the deficiency and, above all, protecting maternal and fetal health in at-risk populations.

Bibliography
1. Bailey LB, ed. Folate in health and disease. CRC Press. 2nd ed. 2010.
2. Bailey LB, Stover PJ, McNulty H, et al. Biomarkers of Nutrition for Development—Folate Review. J Nutr. 2015;145(7):1636S–1680S.
3. Koury MJ, Ponka P. New insights into erythropoiesis: the roles of folate, vitamin B12, and iron. Annu Rev Nutr. 2004;24:105–131.
4. World Health Organization. Serum and red blood cell folate concentrations for assessing folate status in populations. Geneva: WHO; 2015.
5. Hoffbrand AV. Megaloblastic anaemia. In: Hoffbrand AV, Higgs DR, Keeling DM, Mehta AB, eds. Postgraduate Haematology. 7th ed. Wiley-Blackwell; 2016:53–71.
6. Schwahn B, Rozen R. Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am J Pharmacogenomics. 2001;1(3):189–201.
7. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202.
8. Bibbins-Domingo K, et al. Folic Acid Supplementation for the Prevention of Neural Tube Defects: US Preventive Services Task Force Recommendation Statement. JAMA. 2017;317(2):183–189.
9. De Benoist B, et al. Conclusions of a WHO Technical Consultation on folate and vitamin B12 deficiencies. Food Nutr Bull. 2008;29(2 Suppl):S238–S244.
10. Devalia V, Hamilton MS, Molloy AM. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol. 2014;166(4):496–513.